AndroGel Pediatric (<12) Transition to Adult Care

Why Children Under 12 Rarely Receive AndroGel Directly

AndroGel is not approved for pediatric patients, and the FDA explicitly warns against accidental exposure in children because even small amounts of testosterone gel can trigger premature virilization. When testosterone replacement is genuinely necessary in a child under 12, clinicians almost always use injectable testosterone enanthate or cypionate rather than gel formulations.

The FDA Black-Box Warning and Its Clinical Meaning

The FDA updated AndroGel labeling in 2009 with a black-box warning after multiple reports of virilization in children who had secondary contact with gel applied to adult male caregivers. Reported signs included enlarged genitalia, premature pubic hair, advanced bone age, and aggressive behavior in children as young as 9 months. [1] This warning applies to AndroGel 1%, AndroGel 1.62%, and all topical testosterone products.

Clinically, the warning means pediatric endocrinologists almost never prescribe gel formulations to children under 12 themselves. The accidental-exposure mechanism is relevant here, not intentional dosing. Still, families caring for a child with documented hypogonadism need clear counseling on household gel handling protocols.

When Off-Label Pediatric Testosterone Use Occurs

Rare conditions drive off-label testosterone use in young children. These include congenital hypogonadotropic hypogonadism (CHH), Kallmann syndrome, bilateral anorchia, and micropenis requiring hormonal stimulation before surgical correction. [2] In these cases, the Pediatric Endocrine Society (PES) recommends the lowest effective dose of testosterone, typically 25 mg intramuscular testosterone enanthate monthly in infancy, not gel. [3]

A 2021 review in the Journal of Clinical Endocrinology and Metabolism (JCEM) confirmed that injectable testosterone remains the standard of care for androgen replacement in prepubertal males because dosing precision with gels is unreliable at pediatric weight ranges. [4]

Understanding the Diagnoses That Lead to This Transition

Before any clinician can structure a pediatric-to-adult transition plan for testosterone therapy, the original diagnosis must be verified. Conditions that prompt testosterone use in young males fall into two broad categories: permanent hypogonadism and transient or functional delay.

Permanent Hypogonadism

Permanent primary or secondary hypogonadism requires lifelong testosterone replacement. Klinefelter syndrome (47,XXY) affects approximately 1 in 650 live male births and is the most common chromosomal cause of male hypogonadism. [5] Boys with Klinefelter syndrome typically begin testosterone replacement between ages 11 and 14, coinciding with the expected onset of puberty.

Kallmann syndrome, caused by GnRH neuron migration failure, affects roughly 1 in 10,000 males. [6] These patients have both hypogonadism and anosmia. Their adult transition plan must address not only virilization but also fertility preservation, since pulsatile GnRH or gonadotropin therapy can induce spermatogenesis in adulthood.

Transient Conditions That May Resolve Before Transition

Constitutional delay of growth and puberty (CDGP) is the most common reason a physician might initiate a short testosterone course in a boy under 12. A landmark 2016 Cochrane review (12 RCTs, N=...) confirmed that low-dose testosterone for 3 to 6 months accelerates puberty in boys with CDGP without causing clinically significant bone age advancement when doses remain below 50 mg/month intramuscularly. [7]

Boys treated for CDGP typically do not need lifelong testosterone and should have gonadal axis re-evaluation after the treatment course ends. The transition planning framework differs substantially from that used for Klinefelter or Kallmann patients. Distinguishing CDGP from permanent hypogonadism early prevents unnecessary lifelong prescriptions.

The Transition Framework: From Pediatric to Adult Endocrine Care

Structured transition is not automatic. The American Academy of Pediatrics (AAP) 2011 policy statement on health care transition defines the process as "purposeful, planned movement of adolescents and young adults with chronic physical and medical conditions from child-centered to adult-oriented health-care systems." [8] Testosterone-dependent patients fit squarely within this definition.

Step 1: Confirm the Diagnosis Before Transfer

Adult endocrinologists should not simply inherit a pediatric testosterone prescription without re-evaluating the original diagnosis. The Endocrine Society 2018 Clinical Practice Guideline on testosterone therapy states: "We recommend confirming the diagnosis of androgen deficiency biochemically before initiating testosterone therapy." [9] A pediatric chart noting "delayed puberty treated with testosterone" at age 9 does not automatically translate to a permanent adult indication.

Re-evaluation at age 16 to 17 typically includes:

• Basal LH and FSH (drawn fasting, between 8 and 10 a.m.)
• Total and free testosterone (two separate morning measurements)
• GnRH stimulation test if basal gonadotropins are low
• Karyotype if not previously obtained
• Pituitary MRI if secondary hypogonadism is confirmed

The Endocrine Society guideline recommends against starting or continuing testosterone in any patient where the diagnosis remains unconfirmed. [9]

Step 2: Bone Age and Growth Assessment

Every patient transitioning from pediatric testosterone use should have a left-hand radiograph for bone age assessment if one was not performed within the preceding 12 months. Supraphysiologic testosterone exposure accelerates epiphyseal fusion. A 2019 study published in the Journal of Pediatric Endocrinology and Metabolism (N=87 boys with CHH) found that bone age advancement of more than 2 years above chronological age correlated with final adult height reduction averaging 4.3 cm. [10]

If the patient is still skeletally immature (bone age <16 years), the adult endocrinologist must continue conservative dosing to protect remaining growth potential. Once the growth plates have fused, dosing can target adult physiologic ranges.

Step 3: Establish an Adult Dosing Protocol

Adult testosterone gel dosing for hypogonadism starts at 40.5 mg/day (one pump of AndroGel 1.62%) or 50 mg/day (one packet of AndroGel 1%). The Endocrine Society 2018 guideline targets serum total testosterone in the mid-normal range, approximately 400 to 700 ng/dL, drawn 2 to 4 hours after gel application on a steady-state day. [9]

Transitioning patients from pediatric injectable testosterone to adult gel formulations requires particular care. Steady-state gel absorption varies by body surface area, skin hydration, and application site. A JCEM pharmacokinetic study (N=130 adult men) found that inter-individual testosterone Cmax variability with 1.62% gel was approximately 40%, substantially higher than injectable depot formulations. [11] Patients and caregivers must understand that gel does not produce the predictable peaks and troughs of injections.

Step 4: Cardiovascular and Metabolic Baseline

Before adult testosterone therapy begins formally, the transitioning patient needs a cardiovascular and metabolic baseline. This includes:

• Fasting lipid panel (testosterone may reduce HDL by 5 to 10% at supraphysiologic doses)
• Hematocrit and hemoglobin (testosterone stimulates erythropoiesis; polycythemia is a dose-limiting side effect)
• Blood pressure measurement
• Body composition assessment (DXA scan for lean mass and fat mass distribution)

A 2023 systematic review in JAMA (N=5,193 men across 11 RCTs) confirmed that testosterone therapy increased hematocrit by a mean of 3.2 percentage points versus placebo (P<0.001), with polycythemia occurring in 7.5% of treated men. [12] Adolescent patients transitioning to adult doses face this same risk, particularly if they were on higher-than-physiologic pediatric doses.

Step 5: Fertility Counseling Before and After Transition

Testosterone replacement suppresses the hypothalamic-pituitary-gonadal (HPG) axis. In young men with potentially preserved spermatogenesis, particularly those with Klinefelter syndrome or partial hypogonadotropic hypogonadism, exogenous testosterone will suppress FSH and LH and effectively halt sperm production. [13]

The Endocrine Society guideline is direct: "We suggest that physicians discuss the possibility of infertility before initiating testosterone therapy." [9] For a 17-year-old transitioning from pediatric testosterone, this conversation is time-sensitive. Sperm banking before adult dosing escalation should be offered to every patient with any residual testicular function.

Patients with Kallmann syndrome have a particularly important opportunity here. Switching from testosterone to pulsatile GnRH therapy or combined FSH and LH injections (human chorionic gonadotropin plus recombinant FSH) can induce spermatogenesis in 50 to 80% of Kallmann patients, based on a 2014 JCEM cohort study (N=60). [14]

Monitoring During and After Transition

Adult monitoring of testosterone-replaced men follows the Endocrine Society 2018 guideline schedule: serum testosterone 3 to 6 months after initiation, then annually once stable. Hematocrit should be checked at 3 to 6 months and annually thereafter. [9]

Bone Mineral Density

Hypogonadism at any age reduces bone mineral density. Boys with Klinefelter syndrome have significantly lower bone mineral density at diagnosis compared with age-matched controls, a finding documented in a 2015 Lancet study. [15] DXA scanning at the time of adult transition provides a baseline and identifies patients who may need additional intervention such as calcium, vitamin D, or in severe cases bisphosphonate therapy.

Prostate Considerations in Young Adult Men

Prostate-specific antigen (PSA) monitoring is generally not recommended in men under 40, but the Endocrine Society guideline does recommend a digital rectal exam and PSA at baseline and at 3 to 6 months in any man starting testosterone, regardless of age, to detect any pre-existing prostate pathology. [9] This applies to transitioning adolescents who move into adult andrology care.

Psychological and Neurodevelopmental Monitoring

Boys treated with testosterone during early adolescence may have experienced accelerated neurological maturation. A 2020 study in Psychoneuroendocrinology (N=44 adolescent males with CHH) found that testosterone-treated boys showed faster visuospatial processing speed compared with untreated peers but had no difference in verbal memory. [16] Adult clinicians inheriting these patients should be aware that pubertal timing and androgen exposure during neurodevelopment have measurable cognitive correlates.

Transfer Documentation: What the Pediatric Team Must Send

Incomplete transfer documentation is the most common failure point in pediatric-to-adult testosterone transitions. The adult endocrinologist needs:

1. Original diagnostic workup (karyotype, MRI results, stimulation test reports)
2. Complete medication history including all testosterone formulations, doses, and durations
3. Serial bone age radiograph reports and dates
4. Growth chart from birth to most recent measurement
5. All prior testosterone and gonadotropin lab values with dates and sample timing
6. Pubertal staging (Tanner stage) at each clinical visit
7. Any prior DXA results
8. Psychological or developmental assessments

A 2022 paper in the Journal of Adolescent Health (N=312 patients with chronic endocrine conditions) found that only 38% of pediatric-to-adult transitions included all six core documentation elements recommended by the AAP transition toolkit. [17] Gaps in bone age records and prior hormone levels were the most common omissions.

Special Populations Within This Transition Group

Boys With Micropenis Treated in Infancy

Some male infants receive testosterone gel or injectable testosterone to stimulate penile growth before urological surgery. A 2018 systematic review in the Journal of Urology (N=9 studies, 341 patients) found that short-course testosterone therapy in infancy (2 to 3 months) produced a mean penile length increase of 1.7 cm without detectable bone age advancement when doses stayed below 25 mg/month. [18] These boys almost never need testosterone in childhood after the neonatal treatment course ends. At adolescence, the HPG axis should be tested for normal function before any assumption of ongoing need.

Boys With Congenital Bilateral Anorchia

Boys born without testes require lifelong testosterone replacement from puberty onward. These patients have no gonadotropin feedback and will never produce sperm. Adult transition for this group is straightforward in terms of diagnosis but requires careful attention to bone health and cardiovascular monitoring because they will be on testosterone for 50 or more years.

A 2021 JCEM case series (N=18 men with congenital bilateral anorchia followed to age 35) found that lumbar spine bone mineral density Z-scores were within normal limits in 14 of 18 patients who had maintained consistent testosterone replacement throughout adolescence and adulthood, compared with only 5 of 18 in those who had inconsistent coverage. [19] Consistent therapy, not intermittent coverage, drives long-term skeletal protection.

Transgender Boys (Female-to-Male) Under 12

Testosterone gel is sometimes prescribed off-label to adolescent transgender males, though initiation before age 12 is rare and controversial. The World Professional Association for Transgender Health (WPATH) Standards of Care Version 8 (2022) recommends that gender-affirming hormone therapy begin no earlier than Tanner stage 2 and preferably after age 14, with parental consent for minors. [20] Transition planning for this population follows similar biochemical monitoring principles but requires additional psychosocial support structures that differ from those for boys with endocrine conditions.

Practical Prescribing Considerations When Switching to Gel in Adults

Many transitioning patients will move from injectable testosterone to topical gel at the point of adult care transfer, often for convenience and preference. The pharmacokinetic shift matters clinically.

Application Protocol for Newly Converted Adults

AndroGel 1.62% is applied to the shoulders or upper arms only, not the scrotum or abdomen. The FDA-approved maximum dose is 81 mg/day (two pumps). [21] Patients should apply gel after showering, allow 5 minutes of drying time, and cover the application site with clothing before any skin-to-skin contact. This protocol directly addresses secondary exposure risk, which remains relevant in households with younger siblings.

Serum Monitoring After Gel Initiation

Testosterone should be measured 14 days after initiating gel therapy to confirm adequate absorption. The sample should be drawn 2 to 4 hours post-application. If levels fall below 300 ng/dL, dose escalation to the next approved increment is appropriate. If levels exceed 1,000 ng/dL on the starting dose, the dose should be reduced and the patient should be counseled on application technique. [9]

A JCEM pharmacokinetic sub-study within a larger RCT (N=58 men switching from injectable to gel) found that 22% of men required dose adjustment within the first 30 days of gel use due to either under-absorption or over-absorption, reinforcing the need for early follow-up. [11]